Abbott

# CONFIDENCE IN EXCELLENCE

**HEARTMATE 3™ LVAD**

with Full MagLev™

Flow Technology

## HEARTMATE 3™ LVAD

# DELIVERS EXCELLENT SURVIVAL AND SAFETY OUTCOMES[1]*

**MOMENTUM 3** is the largest left ventricular assist device (LVAD) trial ever conducted, demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.[1]*

## 5-YEAR OUTCOMES FROM THE MOMENTUM 3 TRIAL

### FIRST TIME IN LVAD HISTORY

**5-year data** from a prospective randomized LVAD trial

### HEARTMATE 3 LVAD

is a proven **long-term, life-extending therapy** for patients with advanced heart failure


MEDIAN SURVIVAL
**EXCEEDING 5 YEARS[1]**


58.4%
**SURVIVAL AT 5 YEARS[1]**

THESE OUTCOMES REFLECT ABBOTT'S LEGACY OF DEVELOPING **LIFE-CHANGING TECHNOLOGY.**

See Important Safety Information referenced within.

**Life-prolonging therapy** in a patient population who otherwise would **not be expected to survive beyond 9 months**[1,2]*

**Superiority of the HeartMate 3™ LVAD** driven by a **reduction** in HRAEs[1]

**Survival comparable** to higher-risk transplant patients[1,3]

**HeartMate 3 LVAD has received the highest level of recommendation** (1A) from the AHA, ACC and HFSA joint societies for select Class IV heart failure patients

### SAME HEART. BETTER TOMORROWS.

1 in 26

FOR EVERY 1 PATIENT RECEIVING A HEART TRANSPLANT, 25 WILL DIE**

These data provide compelling evidence that **LVAD therapy can add years to the lives** of patients who do not qualify for or are waiting for a heart transplant.

# IMPROVED SAFETY PROFILE[4]

The **ELEVATE Registry** evaluated real-world experience of the HeartMate 3™ LVAD in a post-approval setting. MOMENTUM 3 trial 5-year extended follow-up showed:

## STROKE[4]

**11%** IN FIRST 2 YEARS

**3.6%** IN YEARS 2–5

In the ELEVATE Registry, all major event types were reduced in the 2–5-year follow-up period compared to 0–2 years, especially HRAEs.[1]

# UNMATCHED LEGACY IN MCS

Evolution of HeartMate™ LVAD

## 1998

**HEARTMATE™ XVE LVAS*****

Pulsatile Flow

**FIRST** LVAS APPROVED

FOR DT OR LONG-TERM USE

## 2008

**HEARTMATE II™ LVAD**

Continuous Flow (Axial)

OVER **27,000** PATIENTS IMPLANTED[5]

## 2017

**HEARTMATE 3™ LVAD**

Continuous Flow (Centrifugal)
With Full MagLev™ Flow Technology

OVER **22,000** PATIENTS IMPLANTED[5]

# EXCELLENCE IS:

Immediate, significant and sustained improvements in functional capacity and quality of life

+30 POINTS

**QUALITY-OF-LIFE SCORE IMPROVED SIGNIFICANTLY**
AND WAS SUSTAINED THROUGH 5 YEARS[4]

EuroQol 5 Dimensions 5 Levels (EQ-5D-5L‡) questionnaire

## ABILITY TO WALK 3 TIMES FARTHER[4]




Note: One football field = 91 m (100 yd).

104 ± 140 m
(approx. 114 yd) at baseline

301 ± 131 m
(approx. 330 yd) at 5 years

## OUTCOMES MADE POSSIBLE BY

# FULL MAGLEV™ FLOW TECHNOLOGY

Full MagLev™ Flow Technology maintains gentle blood handling to minimize complications and reduce HRAEs.

### FULLY LEVITATED, SELF-CENTERING ROTOR

that does not require hydrodynamic or mechanical bearings

### LARGE, CONSISTENT BLOOD FLOW PATHWAYS

to reduce shear stress[6]

### INTRINSIC PULSATILITY

(30 cycles per minute) to reduce blood stasis and minimize thrombus[6,7]


### FULL MAGLEV FLOW TECHNOLOGY PUMP

Large consistent blood flow pathways to reduce shear stress[6]

**167** **STACKED RED BLOOD CELLS[8]**

VS.

### HYDRODYNAMIC BEARING PUMP

Narrow blood flow pathways

**8** **STACKED RED BLOOD CELLS[8]**

See Important Safety Information referenced within.

# HEARTMATE 3™ LVAD SYSTEM

A better experience for clinicians and patients†

**1. HeartMate 3™ LVAD**

Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body

**2. Modular driveline**

Facilitates simple replacement of externalized portion

**3. Batteries**

Provide up to 17 hours of uninterrupted power

**4. Pocket controller**

Powers and controls the LVAD and is small enough to fit in a pocket. Includes emergency backup battery


**Mobile Power Unit (MPU)**

Plug-in power source



# EMBRACE EXCELLENCE
# EVERY DAY

By choosing the HeartMate 3™ LVAD, you can help patients and their loved ones hold on to what matters most.

## INSTRUCT™ PATIENT EDUCATION PATHWAY

**HEARTMATE 3™ LVAD POST-IMPLANT**
**Scan the QR code or text LIFE to 1-844-HEART-34** (1-844-432-7834) to receive 15 daily and four additional monthly post-implant HeartMate 3 LVAD educational messages

**Scan the QR code** to learn more about HeartMate 3 LVAD

ACC = American College of Cardiology‡; AHA = American Heart Association‡; DT = Destination Therapy; EuroQol = European Quality of Life questionnaire; HFSA = Heart Failure Society of America; HRAE= hemocompatibility-related clinical adverse event; LVAD = left ventricular assist device; LVAS = left ventricular assist system; MCS = mechanical circulatory support; MPU = mobile power unit

*HeartMate 3™ LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Patients on inotropes who did not receive a transplant or left ventricular assist device.
***This product is no longer available for sale or use.
†Compared to HeartMate II LVAD.


1. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. *JAMA*. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197
2. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. *Circ Heart Fail*. 2015;8(5):880-886.
3. Kilic A, Weiss ES, Yuh DD, Shah AS, Conte JV. Factors associated with 5-year survival in older heart transplant recipients. *J Thorac Cardiovasc Surg*. 2012;143(2):468-474.
4. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. Presented at: European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.
5. Abbott. Data on File. Based on clinical and device tracking data as of November 10, 2022.
6. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. *Am Soc Artificial Int Organs*. 2016;62(4):375-383.
7. Bourque K, Dague C, Farrar D, et al. *In vivo* assessment of a rotary left ventricular assist device induced artificial pulse in the proximal and distal aorta. *Artificial Organs*. 2006;30(8):638-642.
8. Abbott. Data on File.



**Abbott**
6101 Stoneridge Dr., Pleasanton, CA 94588 USA, Tel: 1 925 847 8600
Cardiovascular.Abbott/HeartMate3


**Rx Only**

**Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

**HeartMate 3™ LVAS Indications:** The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

**HeartMate 3™ LVAS Contraindications:** The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

**HeartMate 3™ LVAS Adverse Events:** Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.



MAT-2010568 v2.0 | Item approved for U.S. use only.


Abbott